When metformin is not enough: Pros and cons of SGLT2 and DPP-4 inhibitors as a second line therapy
Publication date:
2018
Publisher version:
Citación:
Diabetes/Metabolism Research and Reviews, 34(4), p. e2981- (2018); doi:10.1002/dmrr.2981
Descripción física:
p. e2981-
ISSN:
DOI:
Collections
- Artículos [35470]